Infusion Partners Received an FDA Warning Letter
After the 483 Form that we previously discussed is responded to by the outsourcing facility, the FDA has the option to then send an FDA Warning Letter if they're not satisfied with the response and/or action plan that's presented to them. In March of 2019 the FDA issued such an actual Warning Letter